HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IFRX
InflaRx N.V.
There isn't enough reported data to score IFRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IFRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IFRX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IFRX PE Valuation
IFRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IFRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect IFRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IFRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.54 | +$0.27 |
| Q1 2026 | -$0.68 | +$0.16 |
| Q4 2025 | -$0.73 | +$0.14 |
| Q3 2025 | -$0.67 | +$0.40 |
| Q2 2025 | -$0.81 | +$0.07 |
| Q1 2025 | -$0.84 | -$0.07 |
| Q4 2024 | -$0.87 | +$0.02 |
| Q3 2024 | -$1.07 | -$0.25 |
IFRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over IFRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IFRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $26.5K | -81% |
| Q2 2025 | $43.8K | +520% |
| Q3 2024 | $137.6K | +104% |
IFRX's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -39769% | -27364 points |
| Q2 2025 | -32525% | +209675 points |
| Q3 2024 | -12405% | +5934 points |
| Q2 2024 | -242200% | N/A |
| Q1 2024 | -34655% | N/A |
| Q4 2023 | -582075% | N/A |
| Q3 2023 | -18339% | N/A |
IFRX's operating margin was −39769% last quarter, down 5114 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IFRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IFRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9M | +$5.5M |
| Q1 2026 | -$8.4M | +$7.2M |
| Q4 2025 | -$5.2M | +$8M |
| Q3 2025 | -$10.1M | +$592.1K |
| Q2 2025 | -$8.4M | +$5.1M |
| Q1 2025 | -$15.6M | +$953.5K |
| Q4 2024 | -$13.2M | -$1.1M |
| Q3 2024 | -$10.7M | -$4.9M |
IFRX has burned cash in almost every quarter: −$27M over the past year, against −$48M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IFRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IFRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +63% | +45.4M shares |
| 1 year | +74% | +49.9M shares |
| 3 years | +106% | +60.7M shares |
| 5 years | +166% | +73.5M shares |
| Available history | +353% | +91.7M shares |
IFRX has 118M diluted shares, up 74% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
IFRX hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IFRX Net Leverage
IFRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IFRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 15.9 | Oversold |
IFRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IFRX PE vs Healthcare Sector
IFRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IFRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.54 | 19% below |
| 20 week MA | $1.82 | 32% below |
| 50 week MA | $1.55 | 20% below |
| 100 week MA | $1.48 | 16% below |
| 200 week MA | $1.91 | 35% below |
IFRX is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IFRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.33 | $5.05 | +17% |
| 2021 | $5.05 | $4.65 | -7.9% |
| 2022 | $4.65 | $3.25 | -30% |
| 2023 | $3.25 | $1.63 | -50% |
| 2024 | $1.63 | $2.59 | +59% |
| 2025 | $2.59 | $1.10 | -58% |
| 2026 YTD | $1.10 | $1.24 | +13% |
IFRX has the edge over HIMS on returns for 2026, with the stronger performance.